SCHEMBL2910454

SCHEMBL2910454

Cc1cc(S(=O)(=O)c2ccc(F)cc2)ccc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
ALDH1A1 P00352 3/20 0.43
LMNA P02545 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSD11B1 P28845 1/20 0.42
GAA P10253 1/20 0.42
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
HTR6 P50406 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.41
HTR2A P28223 1/20 0.41
KCNH2 Q12809 1/20 0.41
PTGS2 P35354 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5524384 0.89 ALDH1A1 (0.50) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL9756844 0.82 RAPGEF4 (0.54) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL17245005 0.81 TSHR (0.49) HTR2CHTR2BFFAR4ALDH1A1MEN1
SCHEMBL2903363 0.81 HTR2A (0.46) HTR2CHTR2BLMNAHSD11B1HTR6
SCHEMBL20408989 0.78 ALDH1A1 (0.47) HTR2CHTR2BFFAR4ALDH1A1HSD11B1
SCHEMBL830828 0.77 LMNA (0.51) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL8978705 0.76 HSD11B1 (0.47) HTR2CHTR2BFFAR4ALDH1A1LMNA
SCHEMBL79787 0.76 HSD11B1 (0.55) HTR2CHTR2BALDH1A1LMNAMEN1
SCHEMBL30072318 0.76 HSD11B1 (0.55) HTR2CHTR2BALDH1A1LMNAMEN1
SCHEMBL4328574 0.76 HSD11B1 (0.55) HTR2CHTR2BALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415394-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (GB) 2013-04-09 US disclosed
US-8349897-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2013-01-08 US disclosed
US-20120178814-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease LUKER TIMOTHY JON (GB) 2012-07-12 US disclosed
EP-1937633-B8 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2010-12-22 EP disclosed
EP-1937633-B1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2010-08-04 EP disclosed
US-20090036535-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2009-02-05 US disclosed
EP-1937633-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE Astra Zeneca AB (SE) 2008-07-02 EP disclosed
WO-2007039741-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178814-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease BPGM, PPARA, HPD HTR2C 338/4885HTR2B 655/4885FFAR4 216/4885
US-20090036535-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease BPGM, PPARA, HPD HTR2C 338/4885HTR2B 655/4885FFAR4 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.